Effects of gastric inhibitory polypeptide, glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists on Bone Cell Metabolism.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing preclinical and clinical studies
PubMed 28722834 · doi:10.1111/bcpt.12850
What was done
This narrative review synthesized 30 preclinical (in vitro cell culture and rodent models) and clinical investigations evaluating the effects of gastric inhibitory polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and GLP-1 receptor agonists (GLP-1RAs) on bone turnover markers, bone mineral density, bone microarchitecture, and fracture risk.
What was found
The abstract reports no quantitative metrics or effect sizes. Preclinical cell culture and rodent studies demonstrated that GIP inhibits bone resorption, whereas GLP-1 may promote bone formation and enhance bone material properties. However, these effects were not corroborated by clinical studies in humans.
Why it matters
Although incretin receptors are expressed in skeletal tissue, positive preclinical findings on bone metabolism have not translated to confirmed clinical skeletal benefits, indicating that incretin-based therapies cannot currently be assumed to alter human fracture risk or bone density.
Limits
No quantitative data or numerical outcomes are provided in the abstract. As a narrative review rather than a systematic review or meta-analysis, study selection bias is possible. Preclinical and human clinical findings remain discordant, and clinical trial evidence is currently insufficient to determine relevance in humans.
Cited by
- supports GLP-1 receptors are expressed on skeletal muscle cells and bone cells.